ICER Review Of NSCLC Drugs To Include Roche’s Pending Indication For Tecentriq

This article was originally published in The Pink Sheet Daily

24 Jun 2016
News

Cathy Kelly Catherine.Kelly@informa.com

Executive Summary

Institute for Clinical and Economic Review aims to complete cost effectiveness analysis of non-small lung cancer drugs in time for supplemental approval of the newest PD-L1 inhibitor in the space.

Already Registered? Sign in to continue reading.

New to Pink Sheet? Start a free trial today!

Table
View full table

Topics

United States

Subjects
Reimbursement

Related Companies

ASK THE ANALYST
Email

Print
Bookmark
Share

Tags:

BioPharmaceutical United States Reimbursement

You must sign in to use this functionality

Authentication.SignIn.HeadSignInHeader

PS079548

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

PS079548

All set! This article has been sent to my@email.address.

All fields are required. For multiple recipients, separate email addresses with a semicolon.

Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.

ICER Review Of NSCLC Drugs To Include Roche’s Pending Indication For Tecentriq

News

Executive Summary

Related Content

ICER Report Questions Cost-Effectiveness Of PD-1 Drugs In Lung Cancer

Topics

Related Companies

You must sign in to use this functionality

Authentication.SignIn.HeadSignInHeader

Register

Ask The Analyst

Email Article

Sign In To Set a Search Alert